Tango Therapeutics stock jumps 36% after Q4 results, Erasca cancer trial pact
Tango Therapeutics surged about 36% Thursday, propelled by fourth-quarter numbers and news of a fresh partnership with Erasca to study vopimetostat—the company’s lead drug—in pancreatic and lung cancer settings. Shares recently changed hands at $16.83.
